Plättchenfunktion und Gefäßmotilität Thromboxan-mediierte Mechanismen und ihre mögliche therapeutische Beeinflussung

• LITERATUR

• 1 Ambler J, Butler K D, Ku E C, Maguire E D, Smith J R, Wallis R B. CGS-12970: a novel, long acting thromboxane synthetase inhibitor. Br J Pharmacol 1985; 86: 497-504.
• 2 Burke S E, Lefer A M, Smith G M, Smith J B. Prevention of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor. Br J Pharmacol 1983; 15: 975-1015.
• 3 Chan C C, Nathaniel D J, Yuski P J, Hall R A, Ford-Hutchinson A W. Inhibition of prostanoid-mediated platelet aggregation in vivo and in vitro by 3-hydroxy-methyl-dibenzo(b,f)thiepin-5,5-dioxide (L 640.035). J Pharmacol Exp Ther 1984; 229: 276-82.
• 4 Epstein S E, Palmeri S t. Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy. Am J Cardiol 1984; 54: 1245-52.
• 5 Fitzgerald D J, Roy L, Catella F, Fitzgerald G A. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
• 6 Furchgott R F, Zawadzki J V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
• 7 Garcia-Szabo R, Kern D F, Malik A B. Pulmonary vascular response to thrombin: effects of thromboxane synthetase inhibition with OKY-046 und OKY-1581. Prostaglandins 1984; 28: 851-66.
• 8 Gerrard J M, Peller J D, Krick T P, White J G. Cyclic AMP and platelet prostaglandin synthesis. Prostaglandins 1977; 14: 39-45.
• 9 Van der Giessen W J, Zijlstra F J, Berk L, Verdouw P D. The effect of the thromboxane receptor antagonist BM 13.177 on experimentally induced coronary artery thrombosis in the pig. Eur J Pharmacol 1988; 147: 241-8.
• 10 Golino P, Ashton J H, Glas-Greenwalt P, McNatt J, Buja L M, Willerson J T. Mediation of reocclusion by thromboxane A₂ and serotonin after thrombolysis with tissuetype plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988; 77 (03) 678-84.
• 11 Green K, Liska J, Egberg N, Koul B, Ljunberg B, Blombäck M, Vesterqvist O, Semb B. Hemostatic disturbances associated with implantation of an artificial heart. Thromb Res 1987; 48: 349-62.
• 12 Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. J Clin Inv 1987; 80: 1435-45.
• 13 Halushka P V, Cook J A, Wise W C. Beneficial effects of UK 37.248, a thromboxane synthetase inhibitor in experimental endotoxic shock in rat. Br J Clin Pharmacol 1985; 15: 1335-55.
• 14 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sei USA 1975; 72: 2994-8.
• 15 Haurand M, Ullrich V. Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J Biol Chem 1985; 260: 15059-67.
• 16 Holmes H, Weiss H J. Secretable storage pools in platelets. Ann Rev Med 1979; 30: 119-24.
• 17 Korbut R, Dembinska-Kiec A, Swies J, Zmuda A, Gryglewski R J. On the mechanisms of thrombolytic action of thromboxane synthetase inhibitors. Thromb Haemost 1987; 58 (03) 827-30.
• 18 Lam J Y, Chesebro J H, Ateele P M, Badimon L, Fuster V. Is vasospasm related to platelet deposition?. Circulation 1987; 75: 243-8.
• 19 Latta G. Wirkung von Kalziumantagonisten auf Thrombozytenfunktion und Thromboxanbildung bei gesunden Probanden in vitro und in vivo. Dissertation, Köln; 1986
• 20 Lefer A M. Role of thromboxanes in myocardial ischemia and sudden death. In: Role of Chemical Mediators in the Pathophysiology of Acute Illness and Injury. McConn R. (ed.). New York: Raven Press; 1982: 101-9.
• 21 Lefer A M, Okamatsu S, Smith E F, Smith J B. Beneficial effects of a new thromboxane synthetase inhibitor in arachidonate-induced sudden death. Thromb Res 1981; 23: 265-73.
• 22 Lefer A M. Comparison of the actions of thromboxane receptor antagonists in biological systems. Drugs Today 1985; 21: 283-91.
• 23 Lefer A M, Darius H. A pharmacological approach to thromboxane receptor antagonism. Fed Proc 1987; 46: 144-8.
• 24 Lewy R J, Smith J B, Silver M J, Weiner L, Walinsky P. Detection of thromboxane B₂ in peripheral blood of patients with Prinzmetal angina. Prostagland Med 1979; 02: 243-6.
• 25 Maseri A, L’Abatte A, Baroldi G, Chierchia S, Marzilli M, Ballestra A M, Severi S, Parodi O, Biagini A, Distante A, Pesola A. Coronary vasospasm as a possible cause of myocardial infarction. N Engl J Med 1978; 299: 1271-7.
• 26 Meyers K M, Katz J B, Clemmons R M, Smith J B, Holmsen H. An evaluation of the arachidonate pathway of platelets from companion and food-producing animals, mink and man. Thromb Res 1983; 20: 13-5.
• 27 Moncada S, Vane J R. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull 1978; 34: 129-35.
• 28 Moncada S, Palmer R M, Higgs E A. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988; 12: 365-72.
• 29 Needleman P, Raz A, Ferrendell J A, Minkes M. Application of imidazole as a selective inhibitor of thromboxane synthetase in human platelets. Proc Natl Acad Sci US 1977; 74: 1716-20.
• 30 Palmer R M J, Ferrige A G, Moncada S. Nitric oxide release accounts for the biological activity of endothelial derived relaxing factor. Nature 1987; 327: 524-6.
• 31 Patrono C, Ciabattoni G, Pinca E, Piuglese F, Castrucci E, De Salvo M A, Peskar B A. Low dose aspirin and inhibition of thromboxane B₂ production in healthy subjects. Thromb Res 1980; 17: 317-23.
• 32 Patscheke H, Staiger C, Neugebauer G, Kaufmann B, Strein K, Endele R, Stegmeier K H. The pharmacokinetic and pharmacodynamic profile of the thromboxane A₂ receptor blocker BM 13.177. Clin Pharmacol Ther 1986; 39: 145-50.
• 33 Pierucci A, Simonetti B M, Pecci G, Mavrikakis G, Feriozzi S, Cinotti G A, Ciabattoni G, Patrono C. Acute effects of a thromboxane receptor antagonist on renal function in patients with lupus nephritis. Kidney Int 1987; 31: 283-86.
• 34 Piper P J, Vane J R. Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 1969; 223: 29-33.
• 35 Puig-Parellada P, Planas J M. Action of selective inhibitor of thromboxane synthetase on experimental thrombosis induced by arachidonic acid in rabbits. Lancet 1977; II: 40.
• 36 Radomski M W, Palmer R M J, Moncada S. Comparative pharmacology of endothelial derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-7.
• 37 Radomski M W, Palmer R M J, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-46.
• 38 Randall M J, Wilding R R. Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with thromboxane synthetase inhibitor dazoxiben hydrochloride. Thromb Res 1982; 28: 607-16.
• 39 Raz A, Minkes M S, Neddleman P. Endoperoxides and thromboxanes: structural determinants for platelet aggregation and vasoconstriction. Biochim Biophys Acta 1977; 488: 305-11.
• 40 Riess H, Höfling B, von Arnim T, Hiller E. Thromboxane receptor blockade versus cyclooxygenase inhibition: antiplatelet effects in patients. Thromb Res 1986; 42: 235-45.
• 41 Schrör K, Thiemermann C. Treatment of acute myocardial ischemia with a selective antagonist of thromboxane receptors (BM 13.177). Br J Pharmacol 1986; 87: 631-7.
• 42 Shebuski R J, Storer B L, Fujita T. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Thromb Res 1988; 52: 381-92.
• 43 Shimamoto T, Takahashi T, Takashima Y, Montomiya T, Numano F, Kobayashi M. Prevention of by phthalazinol of thromboxane A₂-induced myocardial infarction in rabbits. Proc Jap Acad Ser 1977; 53: 43-8.
• 44 Sinzinger H, Firbas W. Gefäßwandzellen synthetisieren Thromboxan. Wien Klin Wochenschr 1983; 21: 758-60.
• 45 Sinzinger H, Silberbauer K, Kaliman J, Fitscha P. 20 mg Aspirin daily-evidence for a clinical future of this extremely low-dose in arterial disease. VASA 1988; 17: 10-5.
• 46 Smith B J. Pharmacology of thromboxane synthetase inhibitors. Fed Proc 1987; 46: 139-43.
• 47 Smith E F, Lefer A M, Aharony D, Smith J B, Magolda R L, Claremon D, Nicolaou K C. Carbocyclic TXA₂: aggravation of myocardial ischemia by a new TXA₂ analog. Prostaglandins 1981; 21: 443-56.
• 48 Tad a M, Kuzuya T, Inoue M, Kodama K, Mishima M, Yamada M, Inui M, Abe H. Elevation of thromboxane B₂ levels in patients with classic and variant angina pectoris. Circulation 1981; 64: 1107-15.
• 49 Tada M, Hoshida S, Kuzuya T. Augmented platelet reactivity and thromboxane A₂ production possible aggravating factors in unstable angina. Jap Cire J 1986; 50: 181-7.
• 50 Terashita Z, Imura Y, Tanabe M, Kawazoe K, Nishikawa K, Kato K, Terao S. CV4151-pa potent selective thromboxane A₂ synthetase inhibitor. Thromb Res 1986; 41: 223-37.
• 51 Torca M C, Hacker R W, Yükseltron I, Pohlmann V, Meier P, Zimmermann I, Etti H, Bulitta M, Kondor P. Reduction of the veingraft occlusion rate after coronary artery bypass surgery by treatment with a thromboxane receptor antagonist. Eur Heart J 1988; 09 (Suppl. 01) 325-29.
• 52 Tyler H M, Saxton C A, Parry M J. Administration to man of UK 37.248-01, a selective inhibitor of thromboxane synthetase. Lancet 1981; I: 629-32.
• 53 Vermylen J, Carreras L, Schaeven J V, Defreyn G, Machik S J, Verstraete M. Thromboxane synthetase inhibitors as antithrombotic strategy. Lancet 1981; I: 1073-5.
• 54 Wainwright C L, Parratt J R. Antiarrhythmic effects of the thromboxane antagonist BM 13.177. Eur J Pharmacol 1987; 133: 257-64.
• 55 Watkins W D, Huttermeier P C, Kong D, Peterson M B. Thromboxane and pulmonary hypertension following E. coli endotoxin infusion in sheep: effect of an imidazole derivative. Prostaglandins 1982; 23: 273-85.
• 56 Weiss K. Calcium blockers: anti atherosclerotic action via the prostaglandin system. Eicosanoids and Fatty Acids ; Band 6. Sinzinger H, Peskar B, Schrör K. (Hrsg.). Wien: Facultas-Verlag; 1988
• 57 Willis A L, Kuhn D C. A new potential mediator of arterial thrombosis whose biosynthesis is inhibited by aspirin. Prostaglandins 1974; 04: 127-31.